Data / Form D filings / Stemgent, Inc.
Stemgent, Inc.: Form D filings
Stemgent, Inc., a biotechnology company in Cambridge, MA, filed 7 Form D notices with the SEC between 2009 and 2012. The latest, on August 10, 2012, reports $11.3 million sold of a $11.3 million offering to 8 investors.
Find out what Stemgent, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- ONE KENDALL SQUARE, SUITE B6201, Cambridge, MA, 02139
- Phone
- (617) 494-0398
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2007
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506
- SEC identifier (CIK)
- 1429173
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, street, city, state, ZIP and 4 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 10, 2012 | New notice | $11,299,993 | $11,299,993 | $0 | 8 | Jun 4, 2012 | sec.gov |
| Jan 31, 2012 | New notice | $8,797,992 | $6,297,998 | $2,499,994 | 8 | Jan 6, 2012 | sec.gov |
| Oct 28, 2011 | New notice | $600,000 | $584,810 | $15,190 | 6 | Oct 13, 2011 | sec.gov |
| Jun 10, 2011 | Amendment | $14,127,591 | $10,627,591 | $3,500,000 | 8 | Apr 30, 2010 | sec.gov |
| Apr 13, 2011 | New notice | $3,000,000 | $750,000 | $2,250,000 | 8 | Mar 29, 2011 | sec.gov |
| May 13, 2010 | New notice | $10,127,600 | $5,627,599 | $4,500,001 | 6 | Apr 30, 2010 | sec.gov |
| Nov 24, 2009 | New notice | $3,000,000 | $2,700,000 | $300,000 | 2 | Nov 12, 2009 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Ian Ratcliffe | Executive Officer, Director, Promoter | |
| Stefan E. Miltenyi | Director | |
| Ralph E. Christoffersen | Director | |
| Augustine R. Lawlor | Director | |
| Harold R. Werner | Director |
Other biotechnology companies in Massachusetts that filed recently
- Zai Lab Ltd $249.9 million · Nov 9, 2026
- AI3 Bio, Inc. offering · Nov 4, 2026
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
Every Form D from the week of Aug 6, 2012 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Stemgent, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.